Safety and efficacy of human lactoferrin hLF1-11 for the treatment of infectious complications among haematopoietic stem cell transplant recipients part A: clinical study protocol SC12: safety of a single dose of 5 mg of hLF1-11 given to autologous haematopoietic stem cell transplant recipients.
Phase of Trial: Phase I/II
Latest Information Update: 03 Feb 2010
At a glance
- Drugs Lactoferrin 1-11 (Primary)
- Indications Bacterial infections; Mycoses
- Focus Adverse reactions
- Sponsors AM-Pharma
- 24 Aug 2007 New trial record.